Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allogene Therapeutics, Inc.ALLO · Entity 5243 | Chief Financial Officer | March 22, 2023 | March 25, 2023 |
| RELMADA THERAPEUTICS, INC.RLMD · Entity 5498 | Director | May 25, 2023 | May 30, 2023 |
| Revolution Medicines, Inc.RVMD · Entity 606 | Director | June 08, 2023 | June 12, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allogene Therapeutics, Inc.
Report date March 22, 2023 · Filed March 25, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 862,439 |
Reported balance
After 2023-03-22 transaction · row 1
1 source rowRow 1 · 2023-03-22 · Grant · Acquired 558,094 · Balance 862,439 F1: Includes 429,303 of performance RSUs which shall vest as follows: (1) 50% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 50% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.04 · Expires 2033-03-22 | Direct | 432,738 |
Reported balance
After 2023-03-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-22 · Grant · Acquired 432,738 · Balance 432,738 F3: 25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,152,595 |
Reported balance
Holding disclosure · report date 2023-03-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,152,595 F2: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 429,303 of performance RSUs which shall vest as follows: (1) 50% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 50% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period.
F2: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust
F3: 25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.
RELMADA THERAPEUTICS, INC.
Report date May 25, 2023 · Filed May 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2032-12-16 | Direct | 150,000 |
Reported balance
After 2023-05-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-25 · Grant · Acquired 92,958 · Balance 150,000 F1: The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the "Plan"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders. F2: The option vests in 16 equal quarterly installments commencing on March 16, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the "Plan"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders.
F2: The option vests in 16 equal quarterly installments commencing on March 16, 2023.
Revolution Medicines, Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,251 |
Reported balance
After 2023-06-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 5,200 · Balance 21,251 F1: Includes 6,406 Restricted Stock Units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.84 · Expires 2033-06-07 | Direct | 18,400 |
Reported balance
After 2023-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-08 · Grant · Acquired 18,400 · Balance 18,400 F2: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 8, 2023 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 6,406 Restricted Stock Units.
F2: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 8, 2023 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2023 Filed Jun 12, 2023 20:14 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 18,400 | $0.00 Strike: $24.84 | $0.00 |
DisclosureSEC source: 0001610717-23-000132 · form4.xml · derivative · entry 2 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,400 Underlying: Common Stock · 18,400 shares Expires 2033-06-07 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 8, 2023 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:14 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 5,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000132 · form4.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,251 F1 · balance_after: Includes 6,406 Restricted Stock Units. Read SEC document |
| May 25, 2023 Filed May 30, 2023 21:09 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 92,958 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001213900-23-044088 · ownership.xml · derivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 92,958 shares Expires 2032-12-16 F1 · date: The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the "Plan"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders. F2 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 16, 2023. Read SEC document |
| March 22, 2023 Filed Mar 25, 2023 00:17 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to Buy) · Derivative | 432,738 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001593968-23-000527 · primary_01.xml · derivative · entry 3 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 432,738 Underlying: Common Stock · 432,738 shares Expires 2033-03-22 F3 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| March 22, 2023 Filed Mar 25, 2023 00:17 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 558,094 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-23-000527 · primary_01.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 862,439 F1 · shares: Includes 429,303 of performance RSUs which shall vest as follows: (1) 50% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 50% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 21:08 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Tax withholdingCommon Stock | 35,879 | $5.47 | $196,258.13 |
DisclosureSEC source: 0001737287-23-000024 · primary_doc.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,345 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.46 to $5.495, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Includes 320 and 2000 share of the Issuer's common stock acquired by the reporting person on September 15, 2021 and on March 15, 2023 pursuant to an employee stock purchase program, respectively. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:33 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 57,042 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001213900-22-081478 · ownership.xml · derivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,042 Underlying: Common Stock · 57,042 shares Expires 2032-12-16 F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 16, 2023. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 21:04 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 18,400 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001567619-22-013110 · doc1.xml · derivative · entry 2 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,400 Underlying: Common Stock · 18,400 shares Expires 2032-06-15 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 16, 2022 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 21:04 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 5,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013110 · doc1.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,051 F1 · balance_after: Includes 8,215 Restricted Stock Units. Read SEC document |
| May 25, 2022 Filed May 26, 2022 22:41 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 91,235 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-22-029834 · ownership.xml · derivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 91,235 shares Expires 2031-12-17 F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders. F2 · derivative.exercise_date: The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 21:49 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to Buy) · Derivative | 368,589 | $0.00 Strike: $9.69 | $0.00 |
DisclosureSEC source: 0001214659-22-004371 · marketforms-55856.xml · derivative · entry 3 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,589 Underlying: Common Stock · 368,589 shares Expires 2032-03-23 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 21:49 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 237,358 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-004371 · marketforms-55856.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,904 Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 21:58 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 11,469 | $7.63 | $87,550.91 |
DisclosureSEC source: 0001214659-22-004084 · marketforms-55819.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,546 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.59 to $7.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Includes 1021 shares of the Issuer's common stock acquired by the reporting person on March 15, 2022 pursuant to an employee stock purchase program. Read SEC document |
| December 17, 2021 Filed Dec 22, 2021 02:31 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 58,765 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-21-066823 · ownership.xml · derivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,765 Underlying: Common Stock · 58,765 shares Expires 2031-12-17 F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 17, 2022. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 21:17 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 12,659 | $0.00 Strike: $32.93 | $0.00 |
DisclosureSEC source: 0001567619-21-012591 · doc1.xml · derivative · entry 2 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,659 Underlying: Common Stock · 12,659 shares Expires 2031-06-21 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 22, 2021 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 21:17 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 3,617 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-012591 · doc1.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,851 F1 · balance_after: Includes 9,043 Restricted Stock Units. Read SEC document |
| May 24, 2021 Filed May 26, 2021 12:00 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,897 | $0.00 Strike: $18.22 | $0.00 |
DisclosureSEC source: 0001214659-21-005926 · marketforms-52930.xml · derivative · entry 3 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,703 Underlying: Common Stock · 14,897 shares Expires 2030-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| May 24, 2021 Filed May 26, 2021 12:00 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Exercise / conversionCommon Stock | 14,897 | $18.22 | $271,423.34 |
DisclosureSEC source: 0001214659-21-005926 · marketforms-52930.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 20:51 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to Buy) · Derivative | 92,365 | $0.00 Strike: $33.78 | $0.00 |
DisclosureSEC source: 0001214659-21-003603 · marketforms-52123.xml · derivative · entry 3 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,365 Underlying: Common Stock · 92,365 shares Expires 2031-03-26 F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2022, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 20:51 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 24,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-003603 · marketforms-52123.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,097 Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:00 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 8,053 | $38.23 | $307,888.74 |
DisclosureSEC source: 0001214659-21-003238 · marketforms-51916.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,231 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.975 to $38.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Includes 368 shares of the Issuer's common stock acquired by the reporting person on March 15, 2021 pursuant to an employee stock purchase program. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:31 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 400 | $33.29 | $13,314.00 |
DisclosureSEC source: 0001214659-21-000617 · marketforms-50963.xml · nonDerivative · entry 5 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,152,595 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the Eric Schmidt 2017 Family Irrevocable Trust in August 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.17 to $33.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · ownership.nature: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:31 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 11,053 | $32.40 | $358,151.46 |
DisclosureSEC source: 0001214659-21-000617 · marketforms-50963.xml · nonDerivative · entry 4 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,152,995 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the Eric Schmidt 2017 Family Irrevocable Trust in August 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.04 to $33.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · ownership.nature: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:31 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 3,547 | $31.69 | $112,393.43 |
DisclosureSEC source: 0001214659-21-000617 · marketforms-50963.xml · nonDerivative · entry 3 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,164,048 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the Eric Schmidt 2017 Family Irrevocable Trust in August 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · ownership.nature: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust. Read SEC document |
| January 14, 2021 Filed Jan 19, 2021 21:31 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 5,149 | $31.10 | $160,129.27 |
DisclosureSEC source: 0001214659-21-000617 · marketforms-50963.xml · nonDerivative · entry 2 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,167,595 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the Eric Schmidt 2017 Family Irrevocable Trust in August 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · ownership.nature: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust. Read SEC document |
| January 14, 2021 Filed Jan 19, 2021 21:31 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 9,851 | $30.60 | $301,480.99 |
DisclosureSEC source: 0001214659-21-000617 · marketforms-50963.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,172,744 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the Eric Schmidt 2017 Family Irrevocable Trust in August 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · ownership.nature: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 21:10 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 100,000 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0001213900-21-001429 · ownership.xml · derivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-01-07 F1 · derivative.exercise_date: The options vest from the date of grant in quarterly increments of 6.25%. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:36 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 10,366 | $33.00 | $342,078.00 |
DisclosureSEC source: 0001214659-20-009726 · marketforms-50139.xml · nonDerivative · entry 2 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,182,595 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the Eric Schmidt 2017 Family Irrevocable Trust in August 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.93 to $33.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · ownership.nature: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:36 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 4,634 | $32.60 | $151,068.40 |
DisclosureSEC source: 0001214659-20-009726 · marketforms-50139.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,192,961 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the Eric Schmidt 2017 Family Irrevocable Trust in August 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.93 to $32.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · ownership.nature: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 22:55 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 100 | $43.01 | $4,301.00 |
DisclosureSEC source: 0001214659-20-008703 · marketforms-49861.xml · nonDerivative · entry 5 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,197,595 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the Eric Schmidt 2017 Family Irrevocable Trust in August 2020. F3 · ownership.nature: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 22:55 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 2,099 | $42.32 | $88,839.55 |
DisclosureSEC source: 0001214659-20-008703 · marketforms-49861.xml · nonDerivative · entry 4 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,197,695 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the Eric Schmidt 2017 Family Irrevocable Trust in August 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · ownership.nature: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 22:55 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 3,479 | $41.33 | $143,799.59 |
DisclosureSEC source: 0001214659-20-008703 · marketforms-49861.xml · nonDerivative · entry 3 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,199,794 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the Eric Schmidt 2017 Family Irrevocable Trust in August 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.91 to $41.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · ownership.nature: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 22:55 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 4,218 | $40.07 | $169,010.62 |
DisclosureSEC source: 0001214659-20-008703 · marketforms-49861.xml · nonDerivative · entry 2 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,203,273 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the Eric Schmidt 2017 Family Irrevocable Trust in August 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.82 to $40.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · ownership.nature: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 22:55 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 5,104 | $39.47 | $201,441.61 |
DisclosureSEC source: 0001214659-20-008703 · marketforms-49861.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,207,491 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the Eric Schmidt 2017 Family Irrevocable Trust in August 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.80 to $39.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · ownership.nature: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust. Read SEC document |
| September 21, 2020 Filed Sep 22, 2020 20:48 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 1,911 | $37.04 | $70,783.44 |
DisclosureSEC source: 0001214659-20-008039 · marketforms-49727.xml · nonDerivative · entry 3 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,212,595 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the Eric Schmidt 2017 Family Irrevocable Trust on August 18, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.71 to $37.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · ownership.nature: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust. Read SEC document |
| September 21, 2020 Filed Sep 22, 2020 20:48 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 3,200 | $35.96 | $115,069.12 |
DisclosureSEC source: 0001214659-20-008039 · marketforms-49727.xml · nonDerivative · entry 2 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,214,506 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the Eric Schmidt 2017 Family Irrevocable Trust on August 18, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.47 to $36.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · ownership.nature: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust. Read SEC document |
| September 21, 2020 Filed Sep 22, 2020 20:48 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 9,889 | $34.76 | $343,692.20 |
DisclosureSEC source: 0001214659-20-008039 · marketforms-49727.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,217,706 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the Eric Schmidt 2017 Family Irrevocable Trust on August 18, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.34 to $35.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · ownership.nature: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 19:33 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 25,318 | $0.00 Strike: $36.57 | $0.00 |
DisclosureSEC source: 0001567619-20-012442 · doc1.xml · derivative · entry 2 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,318 Underlying: Common Stock · 25,318 shares Expires 2030-06-16 F2 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares subject to the option will vest on each monthly anniversary measured from June 17, 2020 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 19:33 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 7,234 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-012442 · doc1.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,234 F1 · balance_after: Includes 7,234 Restricted Stock Units. Read SEC document |
| April 09, 2020 Filed Apr 9, 2020 20:37 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | OtherWarrants to purchase common stock · Derivative | 12,500 | $9.00 Strike: $9.00 | $112,500.00 |
DisclosureSEC source: 0001213900-20-008907 · ownership.xml · derivative · entry 4 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2024-05-14 Read SEC document |
| April 09, 2020 Filed Apr 9, 2020 20:37 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | OtherWarrants to purchase common stock · Derivative | 32,500 | $6.00 Strike: $6.00 | $195,000.00 |
DisclosureSEC source: 0001213900-20-008907 · ownership.xml · derivative · entry 3 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,500 shares Expires 2023-12-03 Read SEC document |
| April 09, 2020 Filed Apr 9, 2020 20:37 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | OtherCommon Stock | 12,500 | $9.00 | $112,500.00 |
DisclosureSEC source: 0001213900-20-008907 · ownership.xml · nonDerivative · entry 2 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Read SEC document |
| April 09, 2020 Filed Apr 9, 2020 20:37 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | OtherCommon Stock | 32,500 | $6.00 | $195,000.00 |
DisclosureSEC source: 0001213900-20-008907 · ownership.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:36 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to Buy) · Derivative | 109,600 | $0.00 Strike: $18.22 | $0.00 |
DisclosureSEC source: 0001214659-20-002803 · marketforms-48392.xml · derivative · entry 3 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,600 Underlying: Common Stock · 109,600 shares Expires 2030-03-17 F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:36 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 30,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-002803 · marketforms-48392.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,706 Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:32 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 300 | $20.25 | $6,075.00 |
DisclosureSEC source: 0001214659-20-002735 · marketforms-48344.xml · nonDerivative · entry 2 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,906 F1 · kind: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: Includes 949 shares of the Issuer's common stock acquired by the reporting person on March 16, 2020 pursuant to an employee stock purchase program. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:32 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 5,150 | $19.70 | $101,432.86 |
DisclosureSEC source: 0001214659-20-002735 · marketforms-48344.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,257 F1 · kind: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.16 to $20.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 22:14 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | OtherCommon Stock | 237,155 | $25.30 | $6,000,021.50 |
DisclosureSEC source: 0001214659-20-001733 · marketforms-47856.xml · nonDerivative · entry 2 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,227,595 F2 · kind: The reporting person made a previous irrevocable commitment to contribute shares of the Issuer's common stock to an exchange fund in exchange for shares of the exchange fund. The Issuer's common stock was valued at the closing price on February 19, 2020 of $25.30 per share. F2 · price: The reporting person made a previous irrevocable commitment to contribute shares of the Issuer's common stock to an exchange fund in exchange for shares of the exchange fund. The Issuer's common stock was valued at the closing price on February 19, 2020 of $25.30 per share. F3 · ownership.nature: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:21 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantEmployee Stock Option (Right to Buy) · Derivative | 83,500 | $0.00 Strike: $26.89 | $0.00 |
DisclosureSEC source: 0001209191-19-019762 · doc4.xml · derivative · entry 3 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,500 Underlying: Common Stock · 83,500 shares Expires 2029-03-12 F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:21 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 49,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-019762 · doc4.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,400 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.